Up to $1.9 billion, China Biopharmaceuticals and AstraZeneca reach an exclusive authorization cooperation for TQC3721

China Biopharmaceutical announced that it has licensed the overseas rights of its self-developed innovative drug for chronic obstructive pulmonary disease (COPD), TQC3721 (a PDE3/4 inhibitor), to AstraZeneca in total up to $1.9 billion. This is the second major BD transaction China Biopharmaceutical has seen this year.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned